Systematic Review

Antiviral Treatment against Monkeypox: A Scoping Review

Brando Ortiz-Saavedra 1, Darwin A. León-Figueroa 2,3, Elizbet S. Montes-Madariaga 1, Alex Ricardo-Martínez 4, Niza Alva 4, Cielo Cabanillas-Ramirez 4, Joshua J. Barboza 5,*, Abdelmonem Siddiq 6,*, Luis A. Coaguila Cusicanqui 7, D. Katterine Bonilla-Aldana 8 and Alfonso J. Rodríguez-Morales 9,10,11,12

1. Introduction

During the COVID-19 pandemic, increased reporting of human monkeypox virus infection cases spreading in many countries outside of Africa is a major cause for concern [1].
As of 21 October 2022, 75,348 confirmed cases of monkeypox (MPX) have been reported in 109 countries worldwide [2].

MPX is a zoonotic viral disease caused by the monkeypox virus (MPXV) [3]. MPXV is a double-stranded DNA virus of the genus Orthopoxvirus of the family Poxviridae known for more than half a century but geographically restricted to a limited number of endemic countries in Central and West Africa [4].

The transmission of MPX to humans occurs mainly through contact with body fluids, skin lesions, or respiratory droplets from animals infected directly or indirectly through contaminated fomites [5]. The symptoms are similar to those of the disease known as smallpox, with MPX usually involving fever, a skin rash that is more common on the face and extremities than on the trunk, and lymphadenopathy, which is a characteristic feature of MPX [5], with an incubation period varying from 5 to 21 days [7].

MPXV has two distinct genetic clades: the Central African clade (Congo Basin) and the West African clade [8]. The West African clade is known to have a more favorable prognosis, with a case fatality rate of less than 1%. On the other hand, the Central Basin clade (Central African clade) is more lethal, with a case fatality rate of up to 10% in unvaccinated children [9].

At present, there is no authoritative treatment or adequate evidence-based guideline for the treatment of MPX. Thus, clinical management aims to provide symptomatic treatment, manage complications, and prevent long-term sequelae [4]. Although MPX is usually self-limiting and does not require medical treatment, there are some antiviral treatment alternatives, such as tecovirimat, brincidofovir (BCV), and cidofovir, which have been approved in animal models, but their efficacy has not been measured in humans [10,11]. However, the United States has recommended a licensed vaccine, JYNNEOS (Smallpox and MPX Vaccine, Live, Nonreplicating) for the vaccination of persons at risk of occupational exposure to Orthopoxviruses [12].

Although current vaccines offer cross-protection against MPX, they are not specific against the disease-causing MPXV, and their efficacy has not yet been proven in light of recent outbreaks in several countries [13]. Moreover, as a consequence of the eradication and cessation of smallpox vaccination for four decades, MPXV found an opportunity to re-emerge, but with different characteristics [14].

The objective of the present scoping review is to explore the evidence on antiviral pharmacotherapy available for the treatment of adult patients with MPX.

2. Materials and Methods

2.1. Protocol and Registration

The recommendations of the Preferred Reporting Items for Systematic and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR) [15] and the methodological criteria of the Joanna Briggs Institute were followed in the present scoping review [16]. The protocol was previously registered in the Figshare platform (https://doi.org/10.6084/m9.figshare.20577312.v1) (accessed on 31 August 2022).

2.2. Eligibility Criteria

We included primary research articles on patients over the age of 18 who had a serological diagnosis, Polymerase Chain Reaction (PCR), electron microscopy, or immunohistochemical findings positive for MPX and who received some type of pharmacological treatment with an antiviral mechanism of action. The types of studies included in the present review were case reports, case series, observational studies (cohort, cross-sectional, case-control), and clinical trials (randomized and non-randomized). No language limit was established for the articles, and publications were included until 12 September 2022. Scoping reviews, systematic reviews, narrative reviews, letters to the editor without original results, and conference proceedings and abstracts were excluded.
2.3. Information Sources and Search Strategy

A systematic search was carried out in Pubmed, Embase, Scopus, Web of Science, and the Cochrane Controlled Trials Register (CENTRAL). The search terms used were: “Monkeypox” and “treatment” (Table 1). The searches were completed on 12 September 2022, and four different investigators independently evaluated the search results.

Table 1. Bibliographic search strategy.

| Base         | Search Strategy                                                                 |
|--------------|---------------------------------------------------------------------------------|
| PUBMED       | #1 “Monkeypox” [MH] OR “Monkeypox virus” [MH] OR “Monkeypox” [TIAB] OR “Monkey Pox” [TIAB] OR “Monkeypoxvirus*” [TIAB]  
#2 “Therapeutics” [MH] OR “Therapeutic Uses” [MH] OR “Therap**” [TIAB] OR “Treatment**” [TIAB] OR “Pharmaco**” [TIAB] OR “Antiviral**” [TIAB] OR “Management**” [TIAB] OR “Drug**” [TIAB] OR “Agent**” [TIAB]  
#3 = #1 AND #2 |
| SCOPUS       | #1 TITLE-ABS-KEY (“Monkeypox” OR “Monkeypox virus” OR “Monkey Pox” OR “Monkeypoxvirus*”)  
#2 TITLE-ABS-KEY (“Therap**” OR “Treatment**” OR “Pharmaco**” OR “Antiviral**” OR “Management**” OR “Drug**” OR “Agent**”)  
#3 = #1 AND #2 |
| WEB OF SCIENCE | #1 ALL = (“Monkeypox” OR “Monkeypox virus” OR “Monkey Pox” OR “Monkeypoxvirus*”)  
#2 ALL = (“Therap**” OR “Treatment**” OR “Pharmaco**” OR “Antiviral**” OR “Management**” OR “Drug**” OR “Agent**”)  
#3 = #1 AND #2 |
| EMBASE       | #1 ‘monkeypox’/exp OR ‘monkeypox’  
#2 ‘therapy’  
#3 = #1 AND #2 |
| CENTRAL      | #1 “Monkeypox” OR “Monkeypox virus” OR “Monkey Pox” OR “Monkeypoxvirus*”  
#2 “Therap**” OR “Treatment**” OR “Pharmaco**” OR “Antiviral**” OR “Management**” OR “Drug**”  
#3 = #1 AND #2 |

2.4. Study Selection

Three investigators (B.O.-S., D.A.L.-F., and E.S.M.-M.) created a database based on the electronic searches, managed with the appropriate management software (EndNote (Clarivate Analytics, Philadelphia, PA, the United States)), and duplicates were removed. Then, through Rayyan QCRI [17], three researchers (A.M., J.J.B., and N.A.) carried out the screening process, analyzing the titles and abstracts provided by the search independently, choosing those that appeared to meet the inclusion criteria and, if necessary, evaluating the full text. In case of disagreement, the investigators will discuss it until a consensus is reached; in case of a dispute, a fourth investigator will be invited to the discussion to help resolve it.

The authors (A.S., L.A.C.C., D.K.B.-A., and A.J.R.-M.) reviewed the full-text reports and analyzed the inclusion criteria to reach a decision.

2.5. Outcomes

The primary outcome was to report on the antiviral drug therapy available for the treatment of adult patients with MPX.

2.6. Data Collection Process and Data Items

Three investigators independently extracted data from the selected studies into a Microsoft Excel spreadsheet. The following data were extracted from the selected studies: First author, country, year of publication, study design, number of patients, age, sex, method of MPX diagnosis, clinical signs, comorbidities, period of illness, antiviral treatment, dose, mode of administration, discharge, and death. A fourth investigator checked the list of articles and data extractions to ensure that there were no duplicate articles or duplicate
information and resolved discrepancies about study inclusion. The results are summarized in narrative form and tables.

3. Results

3.1. Study Selection

A total of 1927 articles were retrieved using the search strategy. The selection strategy is shown in the prism flow chart (Preferred Reporting Items for Systematic and Meta-Analysis Extension for Scoping Reviews). After the removal of duplicates ($n = 920$), 1007 articles were screened by the reviewers. After filtering the titles and reading the abstracts, 48 articles were selected for full-text reading, and 11 were considered eligible for inclusion in this Scoping Review (Figure 1) [1,18–27].

![Figure 1. PRISMA flowchart summarizing the study selection process.](image)

3.2. Study Characteristics

The main characteristics of the articles included in this scoping review are summarized in Table 2 [1,18–27]. Our scoping review included 11 studies that were published between 1 January and 12 September 2022. The included studies ($n = 11$) reported case reports of MPX applying antiviral treatment, detailed the number of MPX cases, clinical manifestations, number of participants with antiviral treatment, history of sexually transmitted diseases, method of diagnosis, location of skin lesions, drugs used in antiviral treatment, route of
administration, and outcome (Tables 2 and 3) [1,18–27]. A total of 1281 confirmed MPX cases were reported [1,18–27], of which 65 MPX cases had antiviral treatment [1,18–27] distributed in the United States (n = 30) [19,20,22,24], the United Kingdom (n = 6) [18,25,27], Spain (n = 6) [26], Italy (n = 1) [21], France (n = 1) [23], and Others (n = 21) [1] (Table 1). The United States was the country with the highest number of MPX cases receiving antiviral treatment, followed by the United Kingdom and Spain.

Table 2. Characteristics of included studies.

| Authors          | Year | Design          | Country               | Number of Patients (n) | Age (Years) | Sex (M/F) | Sexual Behavior | Previous STIs | HIV Status | Diagnostic Method for Monkeypox | Patients Who Received Antiviral Treatment (n) |
|------------------|------|-----------------|-----------------------|------------------------|-------------|------------|-----------------|--------------|------------|---------------------------------|---------------------------------------------|
| Adler H, et al.  | 2022 | Case series     | United Kingdom        | 1                      | Range (30–40) | M          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 2                      | Range (30–40) | M          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 3                      | Range (30–40) | F          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 4                      | Range (41–50) | M          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 5                      | Range (30–40) | M          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 6                      | Range (<2)    | F          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 7                      | Range (30–40) | F          | NR              | None         | Negative   | RT-PCR                          |                                             |
| Desai AN, et al. | 2022 | Case series     | United States         | 25                     | Median = 40.7 (26–76) | M (n = 25) | MSM             | None         | Positive   | RT-PCR                          | n = 25                                      |
|                  |      |                 |                       |                        |             |            |                 | Possitive    | STI (n = 377) |                              |                                             |
|                  |      |                 |                       |                        |             |            |                 | Positive     | Gonococcal urethritis | Negative RT-PCR                          |                                             |
|                  |      |                 |                       |                        |             |            |                 | Positive     | HIV | Positive RT-PCR                          |                                             |
| Matias WR, et al.| 2022 | Case series     | United States         | 1                      | 20          | M          | MSM             | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 2                      | 20          | M          | MSM             | None         | Positive   | RT-PCR                          |                                             |
|                  |      |                 |                       | 3                      | 40          | M          | MSM             | None         | Negative   | RT-PCR                          |                                             |
| Thornhill JP, et al. | 2022 | Case series     | 16 countries          | 528                    | Median = 38 (18–68) | M (n = 527) F (n = 6) | Trans (n = 1) | Homosexual (n = 9) | STI (n = 377) |                              |                                             |
|                  |      |                 |                       |                        |             |            |                 | Positive     | Gonococcal urethritis | Negative RT-PCR                          |                                             |
|                  |      |                 |                       |                        |             |            |                 | Positive     | HIV | Positive RT-PCR                          |                                             |
| Moschese D, et al.| 2022 | Case series     | Italy                 | 1                      | 26          | M          | NR              | None         | Negative   | RT-PCR                          | n = 1                                       |
|                  |      |                 |                       | 2                      | 35          | M          | NR              | None         | Negative   | RT-PCR                          |                                             |
|                  |      |                 |                       | 3                      | 34          | M          | NR              | None         | Positive   | RT-PCR                          |                                             |
| Rao AK, et al.   | 2022 | Case report     | United States         | 1                      | NR          | M          | Heterosexual    | None         | None       | RT-PCR                          | n = 1                                       |
| Maihe M, et al.  | 2022 | Cohort study    | France                | 264                    | Median = 35 (30–41) | M (n = 262) F (n = 1) | Trans (n = 1) | MSM (n = 245) | STI (n = 209) |                              |                                             |
|                  |      |                 |                       |                        |             |            |                 | Positive     | HIV | Positive RT-PCR                          |                                             |
| Minhaj, F.S, et al.| 2022 | Case reports    | United States         | 17                     | Median = 40 (28–61) | M (n = 17) | GBMSM (n = 17) | None         | NR         | RT-PCR                          | n = 1                                       |
|                  |      |                 |                       |                        |             |            |                 | Positive     | HIV | Positive RT-PCR                          |                                             |
| Girometti, N, et al. | 2022 | Cohort study    | United Kingdom        | 54                     | Median = 41 (34–45) | M (n = 54) | MSM (n = 54) | None         | Positive   | RT-PCR                          | n = 1                                       |
|                  |      |                 |                       |                        |             |            |                 | Positive     | HIV | Positive RT-PCR                          |                                             |
Table 2. Cont.

| Authors                      | Year | Design     | Country | Number of Patients (n) | Age (Years) | Sex (M/F) | Sexual Behavior | Previous STIs | HIV Status | Diagnostic Method for Monkeypox | Patients Who Received Antiviral Treatment (n) |
|------------------------------|------|------------|---------|------------------------|-------------|-----------|-----------------|--------------|-----------|----------------------------------|---------------------------------------------|
| Tarín-Vicente, E.J. et al.   | 2022 | Cohort study | Spain   | 181                    | Median: 37 (31–42) | M (n = 175) | F (n = 6) | MSM (n = 166) | MSW (n = 15) | HIV (n = 72), Syphilis (n = 13), Chlamydia (n = 10) | Positive (n = 72) | RT-PCR n = 6 |
| Patel, A. et al.             | 2022 | Case report | United Kingdom | 197 | Median: 38 (32–42) | M (n = 197) | MSM (n = 197) | HIV (n = 70), Gonorrhea (n = 43/161), Syphilis (n = 6/163), Herpes simplex (n = 11/157) | Positive (n = 70) | RT-PCR n = 1 |

MSM: men who have sex with men; MSW: men who have sex with women; GBMSM: gay or bisexual or other men who have sex with men; STI: sexually transmitted infection; HIV: human immunodeficiency virus; RT-PCR: Polymerase chain reaction with reverse transcriptase; M/F: Male/Female; NR: No report.

3.3. Demographical Characteristics and Diagnostic Method for Monkeypox

Of the total number of cases (n = 1281) reported with MPX [1,18–27], 1269 (99.1%) cases were male [1,18–27]. The age range of reported MPX cases was 18 to 76 years [1,18–27]. Of the reported cases with MPX, 1226 (95.7%) had the sexual behavior of being men who have sex with men [1,18–27]. The sexually transmitted diseases reported in MPX patients were gonorrhea (n = 89) [1,25,27], syphilis (n = 66) [1,25,27], chlamydia (n = 43) [1,26,27], and herpes simplex (n = 38) [1,25,27], and 458 patients tested positive for Human Immunodeficiency Virus (HIV) [19–21,23,25–27]. All confirmed cases of MPX were diagnosed by reverse transcriptase polymerase chain reaction (RT-PCR) [1,18–27] (Table 2).

3.4. Clinical Manifestations, Localization of Skin Lesions, and Treatment

The most frequent clinical manifestations in patients confirmed with MPX were skin lesions (n = 1253) [1,18–27], fever (n = 821) [1,18–27], lymphadenopathy (n = 800) [1,18–21,23–27], headache (n = 397) [1,18–21,23,24,26,27], myalgia (n = 246) [1,19,20,25,27] and fatigue (n = 103) [1,19,22,24,25,27] (Table 3). The most frequent locations of lesions were the genital area (n = 797) [1,18–21,23–27], trunk (n = 508) [1,18,21,23,24,26,27], upper and lower extremities (n = 557) [1,18–21,23–27], face (n = 379) [1,18,19,21,23,25,27], and perianal area (n = 302) [1,19,21,23–27] (Table 3). The most commonly used drugs for antiviral treatment of MPX were tecovirimat (n = 41) [1,18–20,22–25,27], cidovir (n = 20) [1,21,23,26], and BCV (n = 3) [18] (Table 3). The route of administration for tecovirimat was oral, for cidovir it was parenteral and topical, and for BCV oral [1,18–27]. In addition, some patients reported adverse effects such as headache, fatigue, nausea, and transaminitis [1,18–27]. The majority of patients did not refer to a specific treatment but limited themselves to following the treatments for the sexually transmitted diseases they were suffering from. No deaths were reported; all patients made a full recovery [1,18–27].

Table 3. Characteristics of eligible studies. Clinical manifestations, localization, the evolution of lesions, and treatment of monkeypox cases.

| Authors                      | Number of Patients (n) | Clinical Manifestations | Localization of Skin Lesions | Antiviral Treatment | Route of Administration | Associated Adverse Effects | Outcome     |
|------------------------------|------------------------|------------------------|-------------------------------|---------------------|-------------------------|---------------------------|-------------|
| Adler H, et al. [18]         | 1                      | Skin lesions, lymphadenopathy, fever, and night sweats | Face, scalp, trunk, limbs, palms, glans penis, and scrotum | Brincidofovir 200 mg (one dose) | Oral | Transaminitis | Full recovery |
| 2                            | Skin lesions, lymphadenopathy, fever, and groin swelling | Face, trunk, limbs, palms, soles, and scrotum | Brincidofovir 200 mg (two doses) | Oral | Transaminitis | Full recovery |
| Authors                  | Number of Patients (n) | Clinical Manifestations                                                                 | Localization of Skin Lesions                                                                 | Antiviral Treatment                                | Route of Administration | Associated Adverse Effects | Outcome  |
|-------------------------|------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------|---------------------------|----------|
| Desai AN, et al. [19]   | 25                     | Skin lesions (n = 25), fever (n = 19), lymphadenopathy (n = 13), headache (n = 8), fatigue (n = 7), sore throat (n = 5), chills (n = 5), back pain (n = 3), myalgia (n = 2), nausea (n = 1), and diarrhea (n = 1). | Genital and/or perianal (n = 23), chest (n = 9), arms (n = 13), back (n = 8), face (n = 7), and legs (n = 6). | Tecovirimat every 8 or 12 h for 2 weeks (n = 25) | Oral                   | Fatigue (n = 7), headache (n = 8), nausea (n = 4), itching (n = 2), and diarrhea (n = 2) | Full recovery |
| Matias WR, et al. [20]  | 1                      | Skin lesions, lymphadenopathy, fever, chills, and general malaise.                      | Penis, pubis, and arm                                                                      | Tecovirimat 600 mg twice daily for 2 weeks         | Oral                    | Transaminitis, headache | Full recovery |
| Thornhill JP, et al. [1] | 528                    | Rash or skin lesions (n = 500), fever (n = 330), lymphadenopathy (n = 295), lethargy or exhaustion (n = 216), myalgia (n = 165), headache (n = 145), pharyngitis (n = 113), low mood (n = 54), and proctitis or anorectal pain (n = 75). | Anogenital area (n = 383), trunk or limbs (n = 292), face (n = 134), palms or soles (n = 51), and mucosal lesions (n = 217). | Cidofovir (n = 12), tecovirimat (n = 8), vaccinia immune globulin (n = 1) | Oral and parenteral | NR                        | Full recovery |
| Moschese D, et al. [21] | 1                      | Skin lesions, fever, chills, sweats, and lymphadenopathy                                | Nose, limb                                                                                | Cidofovir 5 mg/kg day 1 and 7                     | Intravenous             | None                       | Full recovery |
|                         | 2                      | Skin lesions, fever, and lymphadenopathy                                               | Head, limbs, and trunk                                                                     | None                                              | NR                      | None                       | Full recovery |
|                         | 3                      | Skin lesions, fever, and lymphadenopathy                                               | Perianal, foot, face, and arm                                                              | None                                              | NR                      | None                       | Full recovery |
| Rao AK, et al. [22]     | 1                      | Purulent rash, diarrhea, vomiting, cough, subjective fever, and fatigue                 | NR                                                                                       | Tecovirimat                                       | Oral                    | None                       | Full recovery |
| Malhe M, et al. [23]    | 264                    | Skin lesions (n = 264), lymphadenopathy (n = 174), fever (n = 171), pharyngitis (n = 51), angina (n = 41), respiratory signs (n = 31), and headaches (n = 89). | Genital area (n = 135), limbs (n = 121), trunk (n = 105), perianal (n = 100), face (n = 88), and palmoplantar area (n = 36). | Two doses of Cidofovir 5 mg/kg, (n = 1)           | Intravenous             | None                       | Full recovery |
| Minhaj, F.S., et al. [24]| 17                     | Skin lesions (n = 17), fatigue or malaise (n = 13), chills (n = 12), lymphadenopathy (n = 9), headache (n = 8), fever (n = 7), body aches (n = 6), sore throat or cough (n = 5), and sweat (n = 4). | Arm (n = 9), trunk (n = 9), legs (n = 8), face (n = 7), hands (n = 6), perianal (n = 6), oral (n = 5), neck (n = 5), genital (penis or vagina) (n = 4), and feet (n = 4). | Tecovirimat (n = 1) | Oral                    | None                       | Full recovery |

**Table 3.** Clinical manifestations and associated outcomes.
### Table 3. Cont.

| Authors                  | Number of Patients (n) | Clinical Manifestations | Localization of Skin Lesions                          | Antiviral Treatment | Route of Administration | Associated Adverse Effects | Outcome   |
|--------------------------|------------------------|-------------------------|-------------------------------------------------------|---------------------|--------------------------|---------------------------|-----------|
| Girometti, N. et al. [25] | 54                     | Skin lesions (n = 54), Fatigue (n = 36), fever (n = 31), lymphadenopathy (n = 30), myalgia (n = 16), and sore throat (n = 11) | Genital (n = 33), perianal (n = 24), upper and lower extremities (n = 27), facial (n = 13), oropharyngeal (n = 4), and torso (n = 14) | Tecovirimat (n = 1) | Oral                      | None                       | Full recovery |
| Tarín-Vicente, E.J. et al. [26] | 181                  | Skin lesions (n = 181), lymphadenopathy (n = 153), influenza-like illness (n = 147), fever (n = 131), headache (n = 96), and sore throat (n = 66) | Genital (n = 100), perianal area (n = 66), oral ulcer (n = 45), perioral (n = 51), hands and feet (n = 108), trunk and extremities (n = 104) | Cidofovir (n = 6) | Cutaneous                  | None                       | Full recovery |
| Patel, A. et al. [27]    | 197                    | Mucocutaneous manifestations (n = 197), fever (n = 122), lymphadenopathy (n = 114), headache (n = 49), fatigue/lethargy (n = 46), myalgia (n = 62), arthralgia (n = 21), back pain (n = 21), and rectal pain or pain on defecation (n = 71) | Face (n = 71), trunk (n = 70), arms/legs (n = 74), hands/feet (n = 56), genitail (n = 111), anus or perianal area (n = 82), and oropharyngeal (n = 27) | Tecovirimat 600 mg twice daily for 14 days (n = 1) | Oral                      | None                       | Full recovery |

NR: No report.

### 4. Discussion

There is currently no approved treatment specifically for MPXV infections [28]. However, antivirals developed for use in smallpox patients may be beneficial against MPX, therefore the objective of the present scoping review is to explore the evidence on antiviral pharmacotherapy available for the treatment of adult patients with MPX. It is important to know the correct management of these patients to help mitigate the disease process in order to avoid possible sequelae and even death.

In total, we included 11 studies involving 1281 patients, with the United Kingdom being the country with the most reported patients. All confirmed cases of MPX were diagnosed by RT-PCR. Most of the patients were male and stated that they had the sexual behavior of being men who have sex with men. This would indicate the importance of the sexual transmission mechanism in the spread of MPX. In addition, 35.7% of patients tested positive for HIV, which could predispose them to a more aggressive development of MPX disease.

According to the World Health Organization, reports that current epidemiological statistics indicate that young males are disproportionately affected, with 98.2% (20,138/20,500) of patients with gender information being male and a median age of 36 years (interquartile range: 30–43 years). A total of 95.8% (9484/9899) of patients with reported sexual orientation were identified as males who have intercourse with men [29].

It was reported that only 5% of patients received antiviral treatment against MPX, most often with tecovirimat or cidofovir. Although there is a lack of information on these substances’ efficacy in humans, animal research and case studies imply that they may be effective [30].

Tecovirimat (ST-246) is an antiviral drug that was approved by the Food and Drug Administration (FDA) for the treatment of smallpox disease. Tecovirimat has activity against orthopoxviruses but no notable activity against other dsDNA viruses [31]. One of the main targets of tecovirimat is the palmitoylated phospholipase F13 or p37. F13 is located in the viral envelope and membrane and is involved in the formation of the extracellular enveloped virus (EVV). EVV is hypothesized to be a major contributor to viral entry, cell-to-cell transmission, and transmission through the bloodstream to distant tissues [31–33]. In the present review, 41 participants received tecovirimat at a dose of 600 mg twice daily for 2 weeks. All participants recovered, while the most frequent adverse effects were fatigue, headache, and nausea. In addition, some patients developed transaminitis. Clinical trials were previously conducted on healthy volunteers, where they evaluated the safety and
pharmacokinetics of tecovirimat [34,35]. In general, adverse effects were mild and did not leave sequelae, the most frequent being headache and nausea [30]. The efficacy of tecovirimat was previously demonstrated in animal models [30,36], but no data are yet available in humans. A multicenter Phase 2 clinical trial evaluated the safety, tolerability, and pharmacokinetics of tecovirimat when administered as a single daily oral dose (400 mg or 600 mg) for 14 days in adult volunteers 18 to 74 years of age and found it to be safe and well tolerated, with no deaths or serious adverse events [35]. Two Phase III clinical trials are currently underway to evaluate the efficacy of tecovirimat for the treatment of MPX (NCT05534984, NCT05534165), both with tentative completion dates of 2023.

Cidofovir is a drug used to treat poxviruses; however, the FDA has only approved its usage in Acquired Immune Deficiency Syndrome (AIDS) patients for cytomegalovirus retinitis. Cidofovir diphosphate (CDV-pp), a prodrug that enters cells and is phosphorylated to its active form by cellular enzymes, has the effect of integrating into the developing DNA strand and slowing DNA synthesis. It can also decrease DNA polymerase’s 3’-5’ exonuclease activity [31]. It has been demonstrated to be effective in treating molluscum contagiosum lesions in individuals with AIDS-related CMV retinitis [37]. It is also effective against bovine smallpox and Tecovirimat-associated eczema [38,39]. There is inadequate clinical evidence to support the efficacy of cidofovir against MPX in humans. However, its in vitro efficacy has been demonstrated on MPX infections in animals [10,40,41]. A clinical trial evaluated the synthesis and in vitro and in vivo activity of cidofovir against a variety of orthopoxviruses, it was found to be a broad-spectrum antiviral with potent activity against orthopoxviruses [42].

BCV is another treatment that was approved by the FDA to treat smallpox in 2021. This drug has shown efficacy in treating other orthopoxviruses. BCV, a lipid conjugate of cidofovir, is an acyclic lipid nucleoside phosphonate that is available orally. Unlike cidofovir, BCV provides fewer toxic effects, such as nephrotoxicity, which has been demonstrated after intravenous (IV) dosing in animals and humans and has benefits such as oral use [31,43]. BCV shows activity against several DNA viruses, mainly the poxviruses as the MPXV [44]. It was evidenced in a study in which 3 MPX patients were treated with a weekly BCV dose of 200 mg, that it demonstrated a reduction of the viral load; however, none of the patients completed the treatment because they reported elevations of hepatic enzymes, without observing other hematological alterations [18]. A clinical trial evaluated the safety of brincidofovir against orthopoxvirus in healthy adult subjects and found it to be safe and well tolerated, with no serious or life-threatening adverse reactions [45]. In addition, a Phase II clinical trial evaluating the use of BCV IV in patients with adenovirus infection is currently underway (NCT04706923). Importantly, clinical trials are still needed to evaluate the efficacy and safety of BCV in MPX.

The situation of this re-emerging zoonotic disease is very worrying and deserves further study on the antiviral treatments that can be used against this disease that is currently affecting several continents and with possible new routes of transmission, even during the COVID-19 pandemic that has not yet ended. Key interventions to prevent MPX outbreaks include a high index of suspicion, early identification, isolation, barrier nursing, and strict infection prevention practices by healthcare workers [46].

Limitations and Strengths

Among the limitations of this scoping review is the small number of eligible participants who received antiviral therapy against MPX. In addition, most of the studies corresponded to case reports and case series, where there was no control group with which to compare the effectiveness of the antiviral drugs used. Therefore, with the current evidence, it is not possible to provide a conclusion regarding the efficacy of antiviral drugs. Future randomized clinical studies with appropriate methods are required to assess the effectiveness of tecovirimat, BCV, cidofovir, and other drugs, particularly in populations thought to be at risk, such as HIV patients. In addition, another limitation is that we did not identify articles from the gray literature. In terms of strengths, the present study has a rigor-
ous methodology since it was conducted by the JBI and PRISMA-ScR guidelines. Likewise, all the processes carried out for the selection of studies were performed independently by two or more authors.

5. Conclusions

MPX has spread rapidly throughout the world, and there is less information on the effectiveness of antiviral drugs in treating this disease. However, because smallpox and MPXV are genetically related, antiviral drugs developed to protect against smallpox could also be used to treat MPXV infections. Patients with compromised immune systems and those who are more likely to develop the severe disease may be advised to take antivirals, such as tecovirimat. According to current studies, symptoms usually resolve with or without treatment; however, future randomized clinical trials are needed to determine the efficacy and safety of tecovirimat, cidofovir and BCV against MPX.

Author Contributions: Conceptualization, B.O.-S., D.A.L.-F., E.S.M.-M., L.A.C.C., A.R.-M., N.A., A.S., J.J.B. and A.J.R.-M.; methodology, J.J.B., L.A.C.C., B.O.-S., A.S., D.A.L.-F. and A.J.R.-M.; software, C.C.-R., D.K.B.-A. and J.J.B.; validation, D.A.L.-F., D.K.B.-A. and J.J.B.; formal analysis, B.O.-S., L.A.C.C. and A.J.R.-M.; investigation, C.C.-R., L.A.C.C., A.S., D.K.B.-A. and A.J.R.-M.; resources, D.A.L.-F. and A.J.R.-M.; data curation, B.O.-S.; writing—original draft preparation, B.O.-S., D.A.L.-F., A.S., L.A.C.C., E.S.M.-M., A.R.-M., N.A., J.J.B., C.C.-R., D.K.B.-A. and A.J.R.-M.; writing—review and editing, B.O.-S., D.A.L.-F. and E.S.M.-M.; visualization, C.C.-R.; supervision, D.A.L.-F.; project administration, A.J.R.-M.; funding acquisition, J.J.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Available upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; et al. Monkeypox Virus Infection in Humans across 16 Countries—April–June 2022. N. Engl. J. Med. 2022, 387, 679–691. [CrossRef] [PubMed]

2. 2022 Monkeypox Outbreak Global Map | Monkeypox | Poxvirus | CDC n.d. Available online: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html (accessed on 9 September 2022).

3. Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. Is monkeypox another reemerging viral zoonosis with many animal hosts yet to be defined? Vet. Quart. 2022, 42, 148–150. [CrossRef] [PubMed]

4. Farahat, R.A.; Sah, R.; El-Sakka, A.A.; Bennmelouka, A.Y.; Kundu, M.; Labieb, F.; Shaheen, R.S.; Abdelaal, A.; Kundu, M.; Labieb, F.; et al. Human monkeypox disease (MPX). Infez. Med. 2022, 30, 372–391. [CrossRef] [PubMed]

5. Alakunle, E.; Moens, U.; Nichinda, G.; Okeke, M.I. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. Viruses 2020, 12, 1257. [CrossRef]

6. Gómez-Cardiel, M.C.; Martín-Sánchez, F.J.; Martínez-Sellés, M.; Molero García, J.M.; Moreno Guillén, S.; Rodriguez-Artalejo, F.; Ruiz-Galiana, J.; Cantón, R.; De Lucas Ramos, P.; García-Botella, A.; et al. Monkeypox in humans: A new outbreak. Rev. Esp. Quimioter. 2022, martín06jul2022. [CrossRef]

7. Ihekweazu, C.; Yinka-Ogunleye, A.; Lule, S.; Ibrahim, A. Importance of epidemiological research of monkeypox: Is incidence increasing? Expert Rev. Anti-Infect. Ther. 2020, 18, 389–392. [CrossRef]

8. Lum, F.M.; Torres-Ruesta, A.; Tay, M.Z.; Lin, R.T.P.; Lye, D.C.; Rénia, L.; Ng, L.F.P. Monkeypox: Disease epidemiology, host immunity and clinical interventions. Nat. Rev. Immunol. 2022, 22, 597–613. [CrossRef]

9. León-Figueroa, D.A.; Bonilla-Aldana, D.K.; Pachar, M.; Romani, L.; Saldaña-Cumpa, H.M.; Anaychay-Zuloeta, C.; Díaz-Torres, M.; Franco-Paredes, C.; Suárez, J.A.; Ramírez, J.D.; et al. The never-ending global emergence of viral zoonoses after COVID-19? The rising concern of monkeypox in Europe, North America and beyond. Travel. Med. Infect. Dis. 2022, 49, 102362. [CrossRef]

10. Rizk, J.G.; Lippi, G.; Henry, B.M.; Forthal, D.N.; Rizk, Y. Prevention and Treatment of Monkeypox. Drugs 2022, 82, 957–963. [CrossRef]

11. Sookaromdee, P.; Wiwanitkit, V. Treatments for Monkeypox. Actas Dermosifiliogr. 2022. [CrossRef]
12. León-Figueroa, D.A.; Barboza, J.J.; Garcia-Vasquez, E.A.; Bonilla-Aldana, D.K.; Díaz-Torres, M.; Saldaña-Cumpa, H.M.; Díaz-Murillo, M.T.; Cruz, O.C.-S.; Rodríguez-Morales, A.J. Epidemiological Situation of Monkeypox Transmission by Possible Sexual Contact: A Systematic Review. *Trop. Med. Infect. Dis.* 2022, 7, 267. [CrossRef] [PubMed]

13. Abdelaal, A.; Reda, A.; Lashin, B.I.; Katamesh, B.E.; Brakat, A.M.; Al-Manaseer, B.M.; Kaur, S.; Asija, A.; Patel, N.K.; Basnyat, S.; et al. Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines? *Vaccines* 2022, 10, 1419. [CrossRef] [PubMed]

14. Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—a potential threat? A systematic review. *PLoS Negl. Trop. Dis.* 2022, 16, e0010141. [CrossRef] [PubMed]

15. Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.J.; Horsley, T.; Weeks, L.; et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann. Intern. Med.* 2018, 169, 467–473. [CrossRef] [PubMed]

16. Peters, M.D.J.; Godfrey, C.M.; Khalil, H.; Mclnerney, P.; Parker, D.; Soares, C.B. Guidance for conducting systematic scoping reviews. *Int. J. Evid. Based Healthc.* 2015, 13, 141–146. [CrossRef]

17. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. *Syst. Rev.* 2016, 5, 210. [CrossRef]

18. Adler, H.; Gould, S.; Hine, P.; Snell, L.B.; Wong, W.; Houlihan, C.F.; Osborne, J.C.; Ramppling, T.; Beadsworth, M.B.; Duncan, C.J.; et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. *Lancet Infect. Dis.* 2022, 22, 1153–1162. [CrossRef]

19. Desai, A.N.; Thompson, G.R.; Neumeister, S.M.; Arutyunova, A.M.; Trigg, K.; Cohen, S.H. Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. *JAMA* 2022, 328, 1348. [CrossRef]

20. Matias, W.R.; Koshy, J.M.; Nagami, E.H.; Kovac, V.; Moeng, L.R.; Shenoy, E.S.; Hooper, D.C.; Madoff, L.C.; Barshak, M.B.; Johnson, A.J.; et al. Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States. *Open Forum Infect. Dis.* 2022, 9, ofac377. [CrossRef]

21. Moschese, D.; Giacomelli, A.; Beltrami, M.; Pozza, G.; Mileto, D.; Reato, S.; Zacheo, M.; Corbellino, M.; Rizzardini, G.; Antinori, S. Hospitalisation for monkeypox in Milan, Italy. *Travel Med. Infect. Dis.* 2022, 49, 102417. [CrossRef]

22. Rao, A.K.; Schulte, J.; Chen, T.-H.; Hughes, C.M.; Davidson, W.; Neff, J.M.; Markarian, M.; Delea, K.C.; Wada, S.; Liddell, A.; et al. Monkeypox in a Traveler Returning from Nigeria—Dallas, Texas, July 2021. *MMWR Morb. Mortal. Wkly. Rep.* 2022, 71, 509–516. [CrossRef] [PubMed]

23. Mailhe, M.; Beaumont, A.-L.; Thy, M.; Le Pluart, D.; Perrineau, S.; Houhou-Fidouh, N.; Deconinck, L.; Bertin, C.; Ferré, V.M.; Cortier, M.; et al. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: An observational cohort study. *Clin. Microbiol. Infect.* 2022. [CrossRef]

24. Minhaj, F.S.; Ogale, Y.P.; Whitehill, F.; Schultz, J.; Foote, M.; Davidson, W.; Hughes, C.M.; Wilkins, K.; Bachmann, L.; Chatelain, R.; et al. Monkeypox Outbreak—Nine States, May 2022. *MMWR Morb. Mortal. Wkly. Rep.* 2022, 71, 764–769. [CrossRef] [PubMed]

25. Girometti, N.; Byrne, R.; Bracchi, M.; Heskin, J.; McOwan, A.; Titte, V.; Gedela, K.; Scott, C.; Patel, S.; Gohil, J.; et al. Demographic and clinical characteristics of confirmed monkeypox virus cases in individuals attending a sexual health centre in London, UK: An observational analysis. *Lancet Infect. Dis.* 2022, 22, 1321–1328. [CrossRef]

26. Tarin-Vicente, E.J.; Alemany, A.; Agud-Dios, M.; Ubals, M.; Sufer, C.; Antón, A.; Arando, M.; Arroyo-Andrés, J.; Calderón-Lozano, L.; Casañ, C.; et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: A prospective observational study. *Lancet Infect. Dis.* 2022, 400, 661–669. [CrossRef]

27. Patel, A.; Bilinska, J.; Tam, J.C.H.; da Silva Fontoura, D.; Mason, C.Y.; Daunt, A.; Snell, L.B.; Murphy, J.; Potter, J.; Tuudah, C.; et al. Clinical features and novel presentations of human monkeypox virus infection in a central London centre during the 2022 outbreak: Descriptive case series. *BMJ* 2022, 378, e072410. [CrossRef]

28. Treatment Information for Healthcare Professionals | Monkeypox | Poxvirus | CDC n.d. Available online: https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html (accessed on 13 September 2022).

29. Multi-Country Outbreak of Monkeypox—External Situation Report 4, Published 24 August 2022—World | ReliefWeb n.d. Available online: https://reliefweb.int/report/world/multi-country-outbreak-monkeypox-external-situation-report-4-published-24-august-2022 (accessed on 25 August 2022).

30. Grosenbach, D.W.; Honeychurch, K.; Rose, E.A.; Chinsangaram, J.; Frimm, A.; Maiti, B.; Lovejoy, C.; Meara, I.; Long, P.; Hruby, D.E. Oral Tecovirimat for the Treatment of Smallpox. *N. Engl. J. Med.* 2018, 379, 44. [CrossRef]

31. Siegrist, E.A.; Sassine, J. Antivirals with Activity Against Monkeypox: A Clinically Oriented Review. *Clin. Infect. Dis.* 2022. [CrossRef]

32. Li, D.; Liu, Y.; Li, K.; Zhang, L. Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis. *J. Infect.* 2022, 85, e99–e101. [CrossRef]

33. Lam, H.Y.I.; Guan, J.S.; Mu, Y. In Silico Repurposed Drugs against Monkeypox Virus. *Molecules* 2022, 27, 5277. [CrossRef]

34. Jordan, R.; Chinsangaram, J.; Bolken, T.C.; Tyavanagitmat, S.R.; Tien, D.; Jones, K.F.; Frimm, A.; Corrado, M.L.; Pickens, M.; Landis, P.; et al. Safety and pharmacokinetics of the antorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. *Antimicrob. Agents Chemother.* 2010, 54, 2560–2566. [CrossRef] [PubMed]
35. Chinsangaram, J.; Honeychurch, K.M.; Tyavanagimatt, S.R.; Leeds, J.M.; Bolken, T.C.; Jones, K.F.; Jordan, R.; Marbury, T.; Ruckle, J.; Mee-Lee, D.; et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. *Antimicrob. Agents Chemother.* 2012, 56, 4900–4905. [CrossRef] [PubMed]
36. Smith, S.K.; Olson, V.A.; Karem, K.L.; Jordan, R.; Hruby, D.E.; Damon, I.K. In vitro efficacy of ST246 against smallpox and monkeypox. *Antimicrob. Agents Chemother.* 2009, 53, 1007–1012. [CrossRef] [PubMed]
37. Meadows, K.P.; Tyring, S.K.; Pavia, A.T.; Rallis, T.M. Resolution of Recalcitrant Molluscum Contagiosum Virus Lesions in Human Immunodeficiency Virus-Infected Patients Treated with Cidofovir. *Arch. Dermatol.* 1997, 133, 987–990. [CrossRef] [PubMed]
38. Becker, C.; Kurth, A.; Hessler, F.; Kramp, H.; Gokel, M.; Hoffmann, R.; Kuczka, A.; Nitsche, A. Cowpox virus infection in pet rat owners: Not always immediately recognized. *Dtsch. Arztebl. Int.* 2009, 106, 329–334. [CrossRef]
39. Graef, S.; Kurth, A.; Auw-Haedrich, C.; Plange, N.; Kern, W.V.; Nitsche, A.; Reinhard, T. Clinicopathological findings in persistent corneal cowpox infection. *JAMA Ophthalmol.* 2013, 131, 1089–1091. [CrossRef]
40. Baker, R.O.; Bray, M.; Huggins, J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. *Antivir. Res.* 2003, 57, 13–23. [CrossRef]
41. Smee, D.F. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. *Antivir. Chem. Chemother.* 2008, 19, 115–124. [CrossRef]
42. Hostetler, K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. *Antivir. Res.* 2009, 82, A84–A98. [CrossRef]
43. Tippin, T.K.; Morrison, M.E.; Brundage, T.M.; Mommeja-Marin, H. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1, A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. *Ther. Drug Monit.* 2016, 38, 777. [CrossRef]
44. Voigt, S.; Hofmann, J.; Edelmann, A.; Sauerbrei, A.; Kühl, J.S. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-I and adenovirus infection after stem cell transplantation. *Transpl. Infect. Dis.* 2016, 18, 791–794. [CrossRef] [PubMed]
45. Chittick, G.; Morrison, M.; Brundage, T.; Nichols, W.G. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. *Antivir. Res.* 2017, 143, 269–277. [CrossRef] [PubMed]
46. Singhal, T.; Kabra, S.K.; Lodha, R. Monkeypox: A Review. *Indian J. Pediatr.* 2022, 89, 955–960. [CrossRef] [PubMed]